References
- Greaves PJ, Gribben JG. Demonstration of durable graft versus lymphoma effects in Hodgkin's lymphoma. J Clin Oncol 2011;29:952–953.
- Peggs KS, Hunter A, Chopra R, . Clinical evidence of a graft-versus-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005;365:1906–1908.
- Porter DL, Stadtmauer EA, Lazarus HM. “GVHD”: graft-versus-host disease or graft-versus-Hodgkin's disease? An old acronym with new meaning. Bone Marrow Transplant 2003;31:739–746.
- Peggs KS, Anderlini P, Sureda A. Allogeneic transplantation for Hodgkin lymphoma. Br J Haematol 2008;143:468–480.
- Robinson SP, Sureda A, Canals C, . Reduced-intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009;94:230–238.
- Peggs KS, Kayani I, Edwards N, . Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol 2011;29:971–978.
- Peggs KS, Sureda A, Qian W, . Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcome. Br J Haematol 2007;139:70–80.
- Anderlini P, Acholonu SA, Okoroji GJ, . Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3 + cell dose, GVHD and disease response. Bone Marrow Transplant 2004;34:511–514.
- Anderlini P, Saliba R, Acholonu S, . Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008;93:257–264.
- Younes A, Bartlett NL, Leonard JP, . Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812–1821.
- Sureda A, Engert A, Browett PJ, . Interim results for the phase II study of panobinostat (LBH589) in patients with relapsed/refractory Hodgkin's lymphoma (HL) after autologous hematopoietic stem cell transplant (AHSCT). J Clin Oncol 2010;28(15 Suppl.): Abstract 8007.
- Gopal AK, Ramchandren R, Berryman RB, . Brentuximab vedotin (SGN-35) treatment in relapsed CD30-positive Hodgkin lymphoma patients following allogeneic stem cell transplant: a multi-centre case series. Bone Marrow Transpl 2011;46(Suppl. 1): Abstract O267.